Browsing publications by Dr Mark Velangi

Newcastle AuthorsTitleYearFull text
Professor Roderick Skinner
Dr Mark Velangi
"We Can Work It out": The Development of a Consensus Approach to Decision Making in Allogeneic Stem Cell Transplantation in the UK2015
Dr Mark Velangi
Professor Roderick Skinner
Dr Sujith Samarasinghe
Similar Outcome of Upfront Unrelated and Matched Sibling Donor Hematopoietic Stem Cell Transplantation in Idiopathic Anlastic Anaemia of Childhood and Adolescence: A Cohort Controlled Study on Behalf of the UK Paediatric BMT WP, of the PD WP and of the SAA WP of the EBMT2014
Professor Roderick Skinner
Dr Mark Velangi
Dr Nicholas Bown
Donor lymphocyte infusions for post-transplant relapse of refractory anemia with excess blasts and monosomy 72008
Dr Tina Biss
Dr Mark Velangi
Dr John Hanley
Failure of rituximab to induce immune tolerance in a boy with severe haemophilia A and an alloimmune factor VIII antibody: a case report and review of the literature2006
Dr Mark Velangi
Dr Michael Reid
Professor Roderick Skinner
Hybrid chemotherapy in two children with acute leukemia of ambiguous lineage2006
Dr Mark Velangi
Elizabeth Matheson
Professor Andy Hall
Dr Julie Irving
Detecting mismatch repair defects in myeloma2005
Dr Mark Velangi
Professor Graham Jackson
Less than half of patients aged 65 years or under with myeloma proceed to transplantation: results of a two region population-based survey2005
Dr Mark Velangi
Reply to Saravanamuttu et al: Uptake of high dose therapy and peripheral blood stem cell transplantation in myeloma patients < 65 years - the role of the myeloma multi-disciplinary team2005
Professor Graham Jackson
Dr Mark Velangi
Only a minority of age eligible patients with myeloma undergo treatment with autologous transplantation. A population based study of the contributory factors. A combined survey on behalf of The Northern Ireland Regional Haematology Group (NIRHG) and The Newcastle Regional Haematology Group (NRHG)2004
Professor Graham Jackson
Dr Mark Velangi
Only a minority of myeloma patients aged under 65 years receive high-dose therapy with autologous transplantation2004
12